Stock analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Schrödinger in a research report issued to clients and investors on Wednesday, February 26th. Leerink ...
today announced that members of its senior leadership team will participate in a fireside chat at the Leerink Partners ...
Molecular Partners will present at TD Cowen and Leerink healthcare conferences and host a financial results call on March 7. Molecular Partners AG, a clinical-stage biotech company focused on ...
Equities research analysts at Leerink Partnrs issued their FY2026 EPS estimates for Kura Oncology in a note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst J. Chang ...
Hosted on MSN1mon
Leerink keeps Eli Lilly stock outperform on revenue growthOn Friday, Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical ...
Leerink analyst Faisal Khurshid downgraded Pliant Therapeutics (PLRX) to Market Perform from Outperform with a price target of $2, down from ...
Stock analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of DENTSPLY SIRONA in a ...
On Wednesday, Leerink Partners adjusted their financial outlook on Cencora Inc (NYSE: COR), increasing the price target to $301 from the previous $287 while keeping an Outperform rating on the stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results